3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Like Vanguard for Healthcare Costs: An Interview With HealthEquity CEO John Kessler
HealthEquity's CEO explains how the company makes money while helping people tackle healthcare savings.
Hot Takes on 6 Hot IPOs
The Industry Focus team weighs in on some of the biggest IPOs and hottest news of the last year.
Bearish Signs and Antitrust Tensions
The Industry Focus hosts gather round the table to talk about (potentially) impending (short-term) doom for the market and big tech.
The Fastest-Growing Healthcare Company You've Never Heard Of
This medical device maker is growing rapidly and has already treated its investors to huge gains. Here's why Wall Street is so excited about where this company is heading.
2018 ASCO Conference Roundup
All your Motley Fool coverage of the 2018 ASCO Conference in one place.
A Promising Step for Medical Marijuana
Medical marijuana enthusiasts, get hyped -- GW Pharma’s advisory committee meeting results could mean huge things for the industry.
Why One Drug Flop Tanked Incyte's Stock
Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.
These 3 Biotechs Just Crushed Analyst Expectations
But before you invest in any of them, you should read this.
3 Key Things Every CAR-T Investor Should Watch
The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn't mean CAR-T stocks are out of the woods just yet.
3 Ways This $30 Billion Market Is Bristol's for the Taking
How this "Big Pharma" is revolutionizing the fight against cancer and well-positioned for long-term growth.
3 Key Pipeline Developments for Gilead Investors to Watch
Forget Hepatitis C -- here are 3 key developments investors should keep on their radars in 2016.